Literature DB >> 27215760

Chagas cardiomyopathy: The potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi.

Fabiane M Santos1, Ana L Mazzeti2, Sérgio Caldas3, Karolina R Gonçalves2, Wanderson G Lima4, Rosália M Torres5, Maria Terezinha Bahia6.   

Abstract

Cardiac involvement represents the main cause of mortality among patients with Chagas disease, and the relevance of trypanocidal treatment to improving diastolic dysfunction is still doubtful. In the present study, we used a canine model infected with the benznidazole-sensitive Berenice-78 Trypanosoma cruzi strain to verify the efficacy of an etiologic treatment in reducing the parasite load and ameliorating cardiac muscle tissue damage and left ventricular diastolic dysfunction in the chronic phase of the infection. The effect of the treatment on reducing the parasite load was monitored by blood PCR and blood culture assays, and the effect of the treatment on the outcome of heart tissue damage and on diastolic function was evaluated by histopathology and echo Doppler cardiogram. The benefit of the benznidazole-treatment in reducing the parasite burden was demonstrated by a marked decrease in positive blood culture and PCR assay results until 30days post-treatment. At this time, the PCR and blood culture assays yielded negative results for 82% of the treated animals, compared with only 36% of the untreated dogs. However, a progressive increase in the parasite load could be detected in the peripheral blood for one year post-treatment, as evidenced by a progressive increase in positive results for both the PCR and the blood culture assays at follow-up. The parasite load reduction induced by treatment was compatible with the lower degree of tissue damage among animals euthanized in the first month after treatment and with the increased cardiac damage after this period, reaching levels similar to those in untreated animals at the one-year follow-up. The two infected groups also presented similar, significantly smaller values for early tissue septal velocity (E' SIV) than the non-infected dogs did at this later time. Moreover, in the treated animals, an increase in the E/E' septal tissue filling pressure ratio was observed when compared with basal values as well as with values in non-infected dogs. These findings strongly suggest that the temporary reduction in the parasite load that was induced by benznidazole treatment was not able to prevent myocardial lesions and diastolic dysfunction for long after treatment.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benznidazole; Diastolic dysfunction; Kinetoplast DNA follow-up; Trypanosoma cruzi

Mesh:

Substances:

Year:  2016        PMID: 27215760     DOI: 10.1016/j.actatropica.2016.05.007

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  9 in total

1.  Low-Level Parasite Persistence Drives Vasculitis and Myositis in Skeletal Muscle of Mice Chronically Infected with Trypanosoma cruzi.

Authors:  Joseph D Weaver; Victoria J Hoffman; Ester Roffe; Philip M Murphy
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Epidemiology and Molecular Typing of Trypanosoma cruzi in Naturally-Infected Hound Dogs and Associated Triatomine Vectors in Texas, USA.

Authors:  Rachel Curtis-Robles; Karen F Snowden; Brandon Dominguez; Lewis Dinges; Sandy Rodgers; Glennon Mays; Sarah A Hamer
Journal:  PLoS Negl Trop Dis       Date:  2017-01-17

Review 3.  Biological factors that impinge on Chagas disease drug development.

Authors:  Amanda F Francisco; Shiromani Jayawardhana; Michael D Lewis; Martin C Taylor; John M Kelly
Journal:  Parasitology       Date:  2017-08-23       Impact factor: 3.234

4.  Performance of recombinant chimeric proteins in the serological diagnosis of Trypanosoma cruzi infection in dogs.

Authors:  Leonardo M Leony; Natália E M Freitas; Rodrigo P Del-Rei; Claudia M Carneiro; Alexandre B Reis; Ana Maria Jansen; Samanta C C Xavier; Yara M Gomes; Edmilson D Silva; Mitermayer G Reis; Deborah B M Fraga; Paola A F Celedon; Nilson I T Zanchin; Filipe Dantas-Torres; Fred L N Santos
Journal:  PLoS Negl Trop Dis       Date:  2019-06-26

5.  Risk factors and select cardiac characteristics in dogs naturally infected with Trypanosoma cruzi presenting to a teaching hospital in Texas.

Authors:  Alyssa C Meyers; Sarah A Hamer; Derek Matthews; Sonya G Gordon; Ashley B Saunders
Journal:  J Vet Intern Med       Date:  2019-05-22       Impact factor: 3.333

6.  New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia.

Authors:  Cristina Alonso-Vega; Julio A Urbina; Sergi Sanz; María-Jesús Pinazo; Jimy José Pinto; Virginia R Gonzalez; Gimena Rojas; Lourdes Ortiz; Wilson Garcia; Daniel Lozano; Dolors Soy; Rosa A Maldonado; Rana Nagarkatti; Alain Debrabant; Alejandro Schijman; M Carmen Thomas; Manuel Carlos López; Katja Michael; Isabela Ribeiro; Joaquim Gascon; Faustino Torrico; Igor C Almeida
Journal:  BMJ Open       Date:  2021-12-31       Impact factor: 2.692

7.  Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy.

Authors:  Elizabeth L Malcolm; Ashley B Saunders; Jordan P Vitt; Bruno G Boutet; Sarah A Hamer
Journal:  J Vet Intern Med       Date:  2022-04-07       Impact factor: 3.175

8.  Echocardiographic Findings in Canine Model of Chagas Disease Immunized with DNA Trypanosoma cruzi Genes.

Authors:  Olivia Rodríguez-Morales; Francisco-Javier Roldán; Jesús Vargas-Barrón; Enrique Parra-Benítez; María de Lourdes Medina-García; Emilia Vergara-Bello; Minerva Arce-Fonseca
Journal:  Animals (Basel)       Date:  2020-04-09       Impact factor: 2.752

9.  The role of fat on cardiomyopathy outcome in mouse models of chronic Trypanosoma cruzi infection.

Authors:  Paul Zaki; Elisa Lbc Domingues; Farhad M Amjad; Maiara B Narde; Karolina R Gonçalves; Mirelle L Viana; Heberth de Paula; Wanderson G de Lima; Huan Huang; Maria T Bahia; Philipp E Sherer; Fabiane M Dos Santos; Louis M Weiss; Herbert B Tanowitz
Journal:  Parasitol Res       Date:  2020-03-24       Impact factor: 2.289

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.